Tyra Biosciences Inc. (NASDAQ: TYRA) is a precision oncology company focused on designing next-generation kinase inhibitors to overcome acquired resistance in cancer patients. Using its in-house SNÅP platform, Tyra develops mutation-targeted therapies with optimized binding and selectivity. Lead programs include treatments for bladder and FGFR-driven cancers. Tyra offers investors an emerging play on structure-guided drug design and personalized cancer therapy.
Ultimi articoli sulle azioni